Surani Salim R, Mendez Yamely, Anjum Humayun, Varon Joseph
Salim R Surani, University of North Texas, Aransas Pass, TX 78366, United States.
World J Gastroenterol. 2016 Jul 14;22(26):6008-15. doi: 10.3748/wjg.v22.i26.6008.
Severe chronic liver disease (CLD) may result from portal hypertension, hepatocellular failure or the combination of both. Some of these patients may develop pulmonary complications independent from any pulmonary pathology that they may have. Among them the hepatopulmonary syndrome (HPS), portopulmonary hypertension (PPH) and hepatic hydrothorax (HH) are described in detail in this literature review. HPS is encountered in approximately 15% to 30% of the patients and its presence is associated with increase in mortality and also requires liver transplantation in many cases. PPH has been reported among 4%-8% of the patient with CLD who have undergone liver transplantation. The HH is another entity, which has the prevalence rate of 5% to 6% and is associated in the absence of cardiopulmonary disease. These clinical syndromes occur in similar pathophysiologic environments. Most treatment modalities work as temporizing measures. The ultimate treatment of choice is liver transplant. This clinical review provides basic concepts; pathophysiology and clinical presentation that will allow the clinician to better understand these potentially life-threatening complications. This article will review up-to-date information on the pathophysiology, clinical features and the treatment of the pulmonary complications among liver disease patients.
严重慢性肝病(CLD)可能由门静脉高压、肝细胞衰竭或两者共同作用引起。其中一些患者可能会出现与自身所患任何肺部病变无关的肺部并发症。在这些并发症中,肝肺综合征(HPS)、门脉性肺动脉高压(PPH)和肝性胸水(HH)将在本综述中详细描述。约15%至30%的患者会出现HPS,其存在与死亡率增加相关,且在许多情况下还需要进行肝移植。PPH在接受肝移植的CLD患者中报告发生率为4% - 8%。HH是另一种病症,患病率为5%至6%,且与无心肺疾病相关。这些临床综合征发生在相似的病理生理环境中。大多数治疗方式仅起临时缓解作用。最终的治疗选择是肝移植。本临床综述提供了基本概念、病理生理学和临床表现,以便临床医生能更好地理解这些潜在的危及生命的并发症。本文将综述有关肝病患者肺部并发症的病理生理学、临床特征和治疗的最新信息。